Anastrozole
| Product Overview |
| Generic Name | Anastrozole |
| Brand Name(s) | Arimidex, Altraz, Anabrez |
| Form | Oral Tablets (film-coated) |
| Strength | 1 mg |
| Therapeutic Class | Endocrine therapy – estrogen synthesis inhibitor |
| ATC Code | L02BG03 |
| Manufacturing & Regulatory |
| Manufacturer | AstraZeneca, Cipla, Sun, Zydus |
| Country | UK, India, Mexico |
| GMP Compliance | WHO‑GMP/EU‑GMP |
| DMF/CEP | USDMF held by multiple suppliers |
| COFEPRIS | Registered in Mexico, Batch-specific specific clave unknown |
| Free Sale Certificate | Yes |
| Logistics & Export |
| MOQ | 100 units |
| Shelf Life | 36 months |
| Storage | Store at room temperature (20–25 °C); protect from moisture |
| Incoterms | EXW/FOB/CIF negotiable |
| Lead Time | 7 - 10 Business Days |
| Documentation |
| Certificate of Analysis (COA) | Provided per batch |
| SDS | Yes—for API and finished product |
| CTD Summary | CTD from originator; generic use abbreviated formats |
Description
Indications & Usage: Anastrozole is a potent non‑steroidal aromatase inhibitor prescribed at 1 mg orally once daily to postmenopausal women with estrogen receptor‑positive breast cancer; demonstrates superior disease‑free survival vs tamoxifen and improved tolerability
Request for Quote
